	Substit	ute for form 1449.	A/PTO		Complete if Known				
					Application Number	09/724,406			
	INF	ORMATIC	ON DIS	SCLOSURE	Filing Date	11/28/2000			
OIPE	STA	TEMENT	BY A	PPLICANT	First Named Inventor	Francisco et al.			
/0	k 0				Art Unit	1642			
	(use as many sheets as necessary)			s necessary)	Examiner Name	Misook Yu			
DEC 8 0 JOO	Speet	1	of	2	Attorney Docket Number	9632-006-999			
3	Æ/								

	U.S. PATENT DOCUMENTS+										
Examiner Initials*	Cite No.	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear						
my		US 2004-0018194 A1	01-29-2004	Francisco et al.							
L		US 2005-0123536 A1	06-09-2005	Law et al.							
				·							
		1			- 1001						

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant				
Initials*	No.'	Country Code ³	Number ⁴	Kind Code ⁴ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Τ°			
248		wo	97/17374		05-15-1997	Medac Gesellschaft	Pages 18-23				
4		wo	05/001038	A2	01-06-2005	Seattle Genetics		 -			

				to the second se	
Examiner Signature	misor	6	Date Considered	3-70-06	

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Occuments at www.uspio.gog or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precade the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

					-			1	
Substitute (for form 1	449B/PTO				Complete if Known			
INFO	INFORMATION DISCLOSURE			<u> </u>	lication Number	10/983,340			
					g Date	November 5, 2904			
סואו	STATEMENT BY APPLICANT				Named Inventor	Doronina, Svetlana O.		1	
4.				Art		1614		1/	
(u		any sheets as		Exa	miner Name	Unassigned	1	166	
Sheet	2	of	2	Atto	mey Docket Numbe	018891-001020US	120	7/00	
						W. M. P.	f¢' √_	1-3-06	
			NON PATE	NT LITER	ATURE DOCUME	NTS /	<i>\</i>)		
Examiner	Cite	Include na	me of the author (in C	APITAL LE	TTERS), title of the an	ticle (when appropriate), title of the item		1	
Initials *	No.1	(DOOK, 1	magazıne, journai, sei pu	nai, symposi blisher, city a	um, catalog, etc.), dat and/or country where	te, page(s), volume issue number(s), published.	T 2		
		D1 +20						1	
			ences Results (2 pages						
		BARTLETT Refractory or 1403.	et al., "Phase I Study of Recurrent CD30 + H	of SGN-30, a ematologic N	Chimeric Monoclona Ialignancies," <u>BLOO</u> I	I Antibody (mAb), in Patients with Vol. 100(11), December, 2002, Abs			
		Safety, Antitu	umor Activity and Pha Patients with Refracto	rmacokinetic ry or Recum	es of Six Weekly Dose ent CD30+ Hematolog	s of SGN-30 (anti-CD30 Monoclonal tic Malignancies," <u>BLOOD</u> 102(11), 200)3,		
		CERVENY e anti-CD30 m	et al., "Hodgkin's disea conoclonal antibody SC	ise growth in GN-30," PRC	hibition and sepsitizat	E 8.			
		CERVENY e	et al., "Signaling via the eutics," <u>LEUKEMIA</u>	e anti-CD30 9:1648-165	nti-CD30 mAb SGM-30 sensitizes Hodgkin's disease cells to conventional 648-1655 (2005).				
		CERVENY e Sensitizes Ce	et al., "The Anti-CD30 ells to Established Che	Monoclonal motherapeut	Antibody SGN-30 Inlics," <u>BLOOD</u> 104(11)	hibits Hodgkins Disease Growth and , 2004, Abs 2639			
		KABAT et al	I., Sequences of Protei	ns of Immun	ological Interest, 5th E	Ed., NIH Publication No. 91-3242, pp. x	/-		
<u> </u>		KOON et al.,	"Anti-CD30 antibody	based therap	py," CURRENT OPIN	IION IN ONCOLOGY 12:588-593 (200	0)		
		LEONARD e Antibody SG	et al., "Targeting CD3(N-30," PROC AM SC	as Therapy C CLIN ON	for Hodgkin's Disease COL April 2005, Abs				
		LEONARD e	et al., "Phase II Study o odgkin's Diseaso," <u>BL</u>	of SGN-30 (/ OOD 104(11	Anti-CD30 Monoclona) 2004, Abs 2635.	ог			
		WAHL et al., vitro and affe	, "The anti-CD30 mon ects antitumor activity	oclonal antib in models of	ody SGN-30 promote Hodgkin's disease," <u>C</u>	in			
,									
			10	nuentr evial u the	no inshut	it, docket number one of these moto applicate. My 4-	hes 3-0	6	
Examiner Signature	V				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's únique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

MAR 1 3 7006 W

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known								
Application Number	09/724,406							
Filing Date	11/28/2000							
First Named Inventor	Francisco et al.							
Art Unit	1642							
Examiner Name	Misook Yu							
Attorney Docket Number	9632-006-999							

my 4-3-06

U.S. PATENT DOCUMENTS+									
	Document Number								
Cite No.1	Number Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
	US 2003-0186384 A1	10-02-2003	Barth et al.						
		-							
			<u> </u>						
									
									
			-						
			- 						

			ļ						
			 						
	Cite No.1		Document Number Publication Date Number Kind Code ² (# known) Publication Date MM-DD-YYYY	Document Number Cite No.' Number Kind Code ² (if known) Publication Date MM-DD-YYYY Applicant of Cited Document US 2003-0186384 A1 10-02-2003 Barth et al.					

			F	OREIGN PA	TENT DOCUM	ENTS		
	Cite	For	eign Patent Docur	nent	J	Name of Detector or	Pages, Columns, Lines,	
	No.1	Country Code ³	Number ⁴	Kind Code ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
my		wo	91/07437	. A2	05-30-1991	Parker, et al		
		wo	01/80880	A2	11-01-2001	Barth, et al		
		DE	19543039	Cl	11-21-1996	Medac Gesellschaft		10

Examiner Signature	Misooh	7	Date Considered	3-30-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

60497666 v1

Express Mail No.: <u>EL 477 035 523 US</u> Sheet <u>1</u> of <u>1</u>

Sheet 1 of 1

-						ATTY, DOCKET NO.		APPLICATION NO.			
IPF						9632-006-999		09/724,406			
∕o∵ ;	.ısfa	F REFERENCES CITE	D BY APPLIC	ANT		APPLICANT					
	(Use several sheets if necessary)				Francisco et al.						
MAR 1 8	Mar S					FILING DATE		GROUP			
4	9	7				November 28, 2000		1642			
TRAD	ENFR		U.S	. PATENT D	OCUM	IENTS			·		
*EXAMINER		DOCUMENT NUMBER	DATE			NAME	CLASS	SUBCLASS		DATE OPRIATE	
DUTTAL	-										
			FORE	IGN PATEN	T DOC	UMENTS					
		DOCUMENT NUMBER DATE				COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							<u> </u>	 	YES	NO	
_											
				- turkinan Austi	- Tit	le Date Partinant Pages Etc.)	<u> </u>	1			
						le, Date, Pertinent Pages, Etc.)				-4:	
my	вм	Bauer al., 1999, "Immu of Cytotoxic Pathways	unotherapy of in Vivo," Can	Human To cer Resea	umors arch, 5	with T-Cell-activating Bispo 9:1961-65.	ecific A	ntibodies:	Stimul	ation	
l	BN	Monoclonal Antibodies	s Against CD3	pecific Targ	geting 8: Pot	and Activation of T Cells Vicential Use for the Treatmen	ia Murii t of Ho	ne Bispecii dgkin's Lyr பார்	ic nphon	na,"	
		Int. J. Cancer 54:820-2						<u></u>		للد	
	во	Renner and Pfreundso Immunoloy Reviews,	chuh, 1995, "7 145:178-209.	fumor The	rapy l	by Immune Recruitment with	n Bispe	Citic Aerob	oeles,	m	
								Ē	200	出	
								- ==	ध	끸	
EXAMINER		Priside V			DATE	CONSIDERED 3-20-	06	1600/290	2002	VEO	
*EXAMINE	R: Initia	00 000	nether or not cita copy of this form	ation is in co n with next o	nforma commu	nce with MPEP 609; Draw line th	rough ci	0			

Sheet 1 of 1 Express Mail No.: EV 335 857 168 US APPLICATION NO. ATTY DOCKET NO. 09/724,406 9632-006 CONFIRMATION NO. LIST OF REFERENCES CITED BY APPLICANT APPLICANT 7578 (Use several sheets if necessary) FRANCISCO et al. GROUPECEIVED FILING DATE 1642 November 28, 2000 U.S. PATENT DOCUMENTS FILING DATE ERIFEROPRIATE CLASS *EXAMINER NAME DATE DOCUMENT NUMBER INITIAL FOREIGN PATENT DOCUMENTS TRANSLATION CLASS SUBCLASS COUNTRY DATE DOCUMENT NUMBER OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) Pohl et al., "CD30-Specific AB1-AB2-AB3 Internal Image Antibody Network: Potential Use as Anti-ΒP Idiotype Vaccine Against Hodgkin's Lymphoma," Int. J. Cancer 54:418-425 (1993) my Weigert et al., "Rearrangement of Genetic Information May Produce Immunoglobulin Diversity," BQ Nature 276:785-790 (1978) 3-20-06 DATE CONSIDERED **EXAMINER** •EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.